CFDE Data Portal | Search GTSE1-DT

	Label	Description
	GTSE1-DT Gene (Entity type)	ENSG00000277232 - GTSE1 divergent transcript
	GSE252944 AKT inhibition 10 v 15 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE218773 ABL2 knockdown Hep-G2 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 10 V 5 CISPLATIN HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE146358 dopamine 3 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE212231 GSE218491 SHP2 inhibition 3 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE248769 1 V 0 SORAFENIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE134191 3 V 1 METFORMIN MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE238018 MXRA8 knockout MDA-MB-231 3 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE165548 gemcitabine 2 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS

GTSE1-DT

ENSG00000277232 - GTSE1 divergent transcript

GSE252944 AKT inhibition 10 v 15 human dn

A Gene Set from LINCS

GSE218773 ABL2 knockdown Hep-G2 2 v 0 human up

A Gene Set from LINCS

GSE216043 10 V 5 CISPLATIN HUMAN UP

A Gene Set from LINCS

GSE146358 dopamine 3 v 7 human dn

A Gene Set from LINCS

GSE212231 GSE218491 SHP2 inhibition 3 v 5 human up

A Gene Set from LINCS

GSE248769 1 V 0 SORAFENIB HUMAN UP

A Gene Set from LINCS

GSE134191 3 V 1 METFORMIN MOUSE DN

A Gene Set from LINCS

GSE238018 MXRA8 knockout MDA-MB-231 3 v 5 human up

A Gene Set from LINCS

GSE165548 gemcitabine 2 v 5 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.